Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 3/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | LIPC | P11150 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12727502 | 0.86 | EGLN3 (0.69) | EGLN3HIF1AAPEX1TSHRCNR1 | |
| SCHEMBL1641775 | 0.86 | EGLN3 (0.81) | EGLN3HIF1ACNR1LMNASMN1; SMN2 | |
| SCHEMBL1642243 | 0.84 | EGLN3 (0.69) | EGLN3HIF1AAPEX1TSHRCNR1 | |
| SCHEMBL1642028 | 0.84 | EGLN3 (0.61) | EGLN3HIF1AAPEX1TSHRCNR1 | |
| SCHEMBL12727509 | 0.84 | EGLN3 (0.68) | EGLN3HIF1ACNR1CNR2 | |
| SCHEMBL1642303 | 0.83 | EGLN3 (0.69) | EGLN3HIF1ACNR1LMNASMN1; SMN2 | |
| SCHEMBL1642095 | 0.82 | EGLN3 (0.66) | EGLN3HIF1ALMNA | |
| SCHEMBL1642313 | 0.81 | EGLN3 (0.57) | EGLN3HIF1ACNR1CNR2 | |
| SCHEMBL12727499 | 0.81 | EGLN3 (0.58) | EGLN3HIF1ACNR1CNR2 | |
| SCHEMBL1641104 | 0.79 | EGLN3 (0.58) | EGLN3HIF1ACNR1CNR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| WO-2009158315-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | EGLN3 3/4885HIF1A 4/4885APEX1 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.